Forty Seven Inc (FTSV) Receives $27.71 Consensus Target Price from Brokerages
Shares of Forty Seven Inc (NASDAQ:FTSV) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $27.71.
FTSV has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Forty Seven in a research note on Monday, January 14th. Zacks Investment Research cut Forty Seven from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. ValuEngine lowered Forty Seven from a “buy” rating to a “hold” rating in a report on Monday, December 17th. BTIG Research started coverage on Forty Seven in a research report on Friday, December 21st. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Oppenheimer set a $35.00 price objective on Forty Seven and gave the company a “buy” rating in a report on Friday, January 11th.
In related news, Director Irving Weissman sold 9,664 shares of the stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $15.02, for a total value of $145,153.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Chris H. Takimoto sold 8,000 shares of the stock in a transaction that occurred on Friday, January 4th. The shares were sold at an average price of $15.55, for a total transaction of $124,400.00. The disclosure for this sale can be found here. Insiders sold 115,363 shares of company stock valued at $1,767,688 over the last quarter.
NASDAQ FTSV opened at $14.58 on Friday. Forty Seven has a 1 year low of $12.02 and a 1 year high of $23.83.
Forty Seven (NASDAQ:FTSV) last issued its earnings results on Tuesday, November 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.17). Analysts expect that Forty Seven will post -3.42 EPS for the current fiscal year.
Forty Seven Company Profile
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.
Further Reading: How to find the components of the quick ratio
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.